Published • loading... • Updated
Biocurious: Lumos seeks to net the 'whales' in US FebriDx rollout
Summary by Stockhead
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Biocurious: Lumos seeks to net the 'whales' in US FebriDx rollout
Lumos’ US viral-versus-bacterial test rollout gaining traction, but the company has pledged to focus on the top-tier operators Doctors misprescribe antibiotics for viral respiratory infections close to half the time Upcoming US flu season will show whether FebriDx sales are nothing to sneeze about Lumos Diagnostics (ASX:LDX) CEO Doug Ward says the company is angling for the “whales and not the minnows” in the US rollout of its viral-versus-bac…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
